OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Asciminib as a third line option in chronic myeloid leukemia
Alessandro Laganà, Emilia Scalzulli, Ida Carmosino, et al.
International Journal of Hematology (2022) Vol. 117, Iss. 1, pp. 16-23
Closed Access | Times Cited: 8
Alessandro Laganà, Emilia Scalzulli, Ida Carmosino, et al.
International Journal of Hematology (2022) Vol. 117, Iss. 1, pp. 16-23
Closed Access | Times Cited: 8
Showing 8 citing articles:
AlphaFold, allosteric, and orthosteric drug discovery: Ways forward
Ruth Nussinov, Mingzhen Zhang, Yonglan Liu, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 6, pp. 103551-103551
Open Access | Times Cited: 53
Ruth Nussinov, Mingzhen Zhang, Yonglan Liu, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 6, pp. 103551-103551
Open Access | Times Cited: 53
Current scenario of pyrazole hybrids with in vivo therapeutic potential against cancers
Zhi Xu, Yafei Zhuang, Qingtai Chen
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115495-115495
Closed Access | Times Cited: 28
Zhi Xu, Yafei Zhuang, Qingtai Chen
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115495-115495
Closed Access | Times Cited: 28
Asciminib, a novel allosteric inhibitor of BCR‐ABL1 , shows synergistic effects when used in combination with imatinib with or without drug resistance
Naoki Okamoto, Kenta Yagi, Sayaka Imawaka, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 4
Naoki Okamoto, Kenta Yagi, Sayaka Imawaka, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 4
Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia
Ayca Irgit, Reyhan Kamıs, Belgin Sever, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 5
Open Access
Ayca Irgit, Reyhan Kamıs, Belgin Sever, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 5
Open Access
Clinical course of chronic myeloid leukemia with T315I mutation of BCR-ABL gene in pediatric and adolescent patients
Polina Sheveleva, Elena Morozova, Anna A. Osipova, et al.
Cellular Therapy and Transplantation (2023) Vol. 12, Iss. 2, pp. 32-39
Open Access | Times Cited: 1
Polina Sheveleva, Elena Morozova, Anna A. Osipova, et al.
Cellular Therapy and Transplantation (2023) Vol. 12, Iss. 2, pp. 32-39
Open Access | Times Cited: 1
Current Progress on the Influence Human Genetics Has on the Efficacy of Tyrosine Kinase Inhibitors Used to Treat Chronic Myeloid Leukemia
Tara C Prakash, Steven A. Enkemann
Cureus (2024)
Open Access
Tara C Prakash, Steven A. Enkemann
Cureus (2024)
Open Access
Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML)
Alessandro Laganà, Emilia Scalzulli, Maria Laura Bisegna, et al.
Expert Review of Hematology (2024)
Closed Access
Alessandro Laganà, Emilia Scalzulli, Maria Laura Bisegna, et al.
Expert Review of Hematology (2024)
Closed Access
Chronic myeloid leukemia: the cutting-edge evidence and things we should know
Noriyoshi Iriyama
International Journal of Hematology (2022) Vol. 117, Iss. 1, pp. 1-2
Open Access | Times Cited: 1
Noriyoshi Iriyama
International Journal of Hematology (2022) Vol. 117, Iss. 1, pp. 1-2
Open Access | Times Cited: 1
